These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 7825631)
1. Androgenic effects of oral contraceptives: implications for patient compliance. Jones EE Am J Med; 1995 Jan; 98(1A):116S-119S. PubMed ID: 7825631 [TBL] [Abstract][Full Text] [Related]
2. Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092 [TBL] [Abstract][Full Text] [Related]
3. A norgestimate-containing oral contraceptive: review of clinical studies. Kafrissen ME Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446 [TBL] [Abstract][Full Text] [Related]
4. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. Crook D; Godsland IF; Wynn V Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933 [TBL] [Abstract][Full Text] [Related]
5. The androgenicity of progestins. Darney PD Am J Med; 1995 Jan; 98(1A):104S-110S. PubMed ID: 7825629 [TBL] [Abstract][Full Text] [Related]
6. Effects of sex steroids on women's health: implications for practitioners. Derman RJ Am J Med; 1995 Jan; 98(1A):137S-143S. PubMed ID: 7825634 [TBL] [Abstract][Full Text] [Related]
7. [Hormonal contraception]. Van Cauwenberge JR Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074 [TBL] [Abstract][Full Text] [Related]
8. The metabolic impact of oral contraceptives. Krauss RM; Burkman RT Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443 [TBL] [Abstract][Full Text] [Related]
9. [Cutaneous effects in hormonal contraception]. Thomas P; Dalle E; Revillon B; Delecour M; Devarenne-nicolle MF; Pagniez I NPN Med; 1985 Jan; 5(81):19-24. PubMed ID: 12281276 [TBL] [Abstract][Full Text] [Related]
17. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751 [TBL] [Abstract][Full Text] [Related]
18. Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status. Potts M; Denny C Drug Saf; 1995 Dec; 13(6):333-7. PubMed ID: 8652077 [TBL] [Abstract][Full Text] [Related]
19. Medical aspects of oral contraceptive discontinuation. Serfaty D Adv Contracept; 1992 Oct; 8 Suppl 1():21-33. PubMed ID: 1442247 [TBL] [Abstract][Full Text] [Related]
20. New knowledge in the physiology of hormonal contraceptives. Lobo RA; Stanczyk FZ Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]